Abstract 320P
Background
Loss of hormone receptors (HR) at breast cancer (BC) metastatic relapse has been reported. Few data are available on the clinicopathologic features associated with HR loss and its prognostic impact.
Methods
We retrospectively identified a cohort of 51 patients (pts) with primary HR+/HER2- BC and triple-negative (TN) metastasis (LUM-TN) along with two control cohorts of paired HR+/HER2- and TN on both primary and metastatic samples (LUM-LUM, n=50; TN-TN, n=49). Clinical features and outcomes were retrieved from medical charts. HR and HER2 status were independently reviewed by two pathologists on all archival samples. Estrogen receptor (ER) expression between 1% and 10% was considered as ER-low. Cox-proportional hazard models were used to assess the impact of variables on distant metastasis-free survival (DMFS) and overall survival (OS).
Results
The three cohorts had no difference in median age, menopausal status nor stage at diagnosis. Pts in LUM-TN cohort had a higher frequency of invasive lobular (20% vs 10% vs 2%, p=.03), primary ER-low BCs (22% vs 0% vs 0%, p<.001) and locoregional relapse (18% vs 0% vs 2%, p<.001) than pts in the LUM-LUM and TN-TN cohorts. Metastatic samples from pts in LUM-TN and LUM-LUM cohorts were more frequently HER2-low than those in TN-TN cohort (57% vs 66% vs 24%, p<.001). At univariate analysis, pts with LUM-TN switch had a longer DMFS compared to the TN-TN (median DMFS 62 vs 18 months; HR 3.35, 95%CI 2.2-5.1, p<.001), but similar to the LUM-LUM cohort (median DMFS 62 vs 64 months; HR 0.95, 95%CI 0.6-1.41, p<.8). The DMFS difference was not significant after adjusting for other variables, including grade and ER-low status. Median OS was significantly lower for pts in LUM-TN (median OS 93 vs 139 months; HR 2.3, 95%CI 1.3-4.1, p<0.004) and TN-TN cohorts (median OS 47 vs 139 months; HR 3.4, 95%CI 1.1-10.7, p<0.03) when compared to the LUM-LUM cohort, independently from other clinicopathologic features.
Conclusions
HR loss at metastatic relapse is frequent in lobular and ER-low primary BCs. Pts with HR loss have similar DMFS compared to pts with maintained HR expression, but apparently reduced OS. Further investigation on biological mechanisms underpinning the LUM-TN phenotype switch is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fondazione Umberto Veronesi, Fondazione IEO – MONZINO, Italian Ministry of Health with Ricerca Corrente 5 x 1000.
Disclosure
M. Ivanova: Financial Interests, Institutional, Research Funding: Fondazione Umberto Veronesi. K. Venetis: Financial Interests, Institutional, Research Funding: Fondazione IEO – MONZINO. G. Curigliano: Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Myers Squibb, Lilly, Novartis, Pfizer, Roche, Seagen, Daiichi Sankyo. N. Fusco: Financial Interests, Institutional, Speaker, Consultant, Advisor: MSD, Boehringer Ingelheim, Novartis, AstraZeneca, Daiichi Sankyo; Financial Interests, Institutional, Funding: Italian Ministry of Health with Ricerca Corrente 5 x 1000 funds. C. Criscitiello: Financial Interests, Institutional, Speaker, Consultant, Advisor: Pfizer, Lilly, Novartis, Roche, Bristol Myers Squibb, Seagen, Daiichi Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02